Miguel Regueiro

Miguel Regueiro

Auto-generated profile, based on publicly available information

Miguel Regueiro

University of Pittsburgh Medical Center

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Gastroenterology
Verified
Journal Article
Closed access
MRMiguel Regueiro
Miguel Regueiro
WSWolfgang Schraut
Wolfgang Schraut
LBLeonard Baidoo
Leonard Baidoo
KKKevin E. Kip
Kevin E. Kip
ASAntonia R. Sepulveda
Antonia R. Sepulveda
SPScott E. Plevy
Scott E. Plevy

4 January 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MSMark S Silverberg
Mark S Silverberg
JCJudy H Cho
Judy H Cho
JRJohn D Rioux
John D Rioux
DMDermot P B McGovern
Dermot P B McGovern
JWJing Wu
Jing Wu
RDRichard H Duerr
Richard H Duerr
Richard Duerr and colleagues present a genome-wide association study of ulcerative colitis. They identify new risk loci on chromosomes 1p36 and 12q15. Ulcerative colitis is a chronic inflammatory disease of the colon that presents as diarrhea and gastrointestinal bleeding. We performed a genome-wide association study using DNA samples from 1,052 individuals with ulcerative colitis and preexisting data from 2,571 controls, all of European ancestry. In an analysis that controlled for gender and population structure, ulcerative colitis loci attaining genome-wide significance and subsequent replication in two independent populations were identified on chromosomes 1p36 (rs6426833, combined P = 5.1 × 10−13, combined odds ratio OR = 0.73) and 12q15 (rs1558744, combined P = 2.5 × 10−12, combined OR = 1.35). In addition, combined genome-wide significant evidence for association was found in a region spanning BTNL2 to HLA-DQB1 on chromosome 6p21 (rs2395185, combined P = 1.0 × 10−16, combined OR = 0.66) and at the IL23R locus on chromosome 1p31 (rs11209026, combined P = 1.3 × 10−8, combined OR = 0.56; rs10889677, combined P = 1.3 × 10−8, combined OR = 1.29).

1 June 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MRMiguel Regueiro
Miguel Regueiro
BFBrian G. Feagan
Brian G. Feagan
BZBin Zou
Bin Zou
JJJewel Johanns
Jewel Johanns
MBMarion A. Blank
Marion A. Blank
ZYZ. Younes
Z. Younes
Most patients with Crohn’s disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence. We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD in 297 patients at 104 sites worldwide from November 2010 through May 2012. All study patients had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 weeks. The primary end point was clinical recurrence, defined as a composite outcome consisting of a CD Activity Index score >200 and a ≥70-point increase from baseline, and endoscopic recurrence (Rutgeerts score ≥i2, determined by a central reader) or development of a new or re-draining fistula or abscess, before or at week 76. Endoscopic recurrence was a major secondary end point. A smaller proportion of patients in the infliximab group had a clinical recurrence before or at week 76 compared with the placebo group, but this difference was not statistically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: −1.3% to 15.5%; P = .097). A significantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.2%; P < .001). Additionally, a significantly smaller proportion of patients in the infliximab group had endoscopic recurrence based only on Rutgeerts scores ≥i2 (22.4% vs 51.3%; ARR with infliximab, 28.9%; 95% confidence interval: 18.4% to 39.4%; P < .001). Patients previously treated with anti-tumor necrosis factor agents or those with more than 1 resection were at greater risk for clinical recurrence. The safety profile of infliximab was similar to that from previous reports. Infliximab is not superior to placebo in preventing clinical recurrence after CD-related resection. However, infliximab does reduce endoscopic recurrence. ClinicalTrials.gov ID NCT01190839.

1 January 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
MRMiguel Regueiro
Miguel Regueiro
KKKevin E. Kip
Kevin E. Kip
WSWolfgang Schraut
Wolfgang Schraut
LBLeonard Baidoo
Leonard Baidoo
ASAntonia R. Sepulveda
Antonia R. Sepulveda
DBDavid Binion
David Binion

1 September 2014 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MRMiguel Regueiro
Miguel Regueiro
KKKevin E. Kip
Kevin E. Kip
LBLeonard Baidoo
Leonard Baidoo
JSJason M. Swoger
Jason M. Swoger
WSWolfgang Schraut
Wolfgang Schraut

1 September 2007 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
MRMiguel Regueiro
Miguel Regueiro
BSBenjamin Siemanowski
Benjamin Siemanowski
KKKevin E. Kip
Kevin E. Kip
SPScott Plevy
Scott Plevy
Background. Crohn's disease (CD) patients who lose response to infliximab may benefit from an increase in dose or decrease in interval between infusions. The ai